HARMONY BIOSCIENCES HOLDINGS (HRMY) Stock Fundamental Analysis
USA - NASDAQ:HRMY - US4131971040 - Common Stock
32.5 USD
+0.11 (+0.34%)
32.5 USD
0 (0%)
We assign a fundamental rating of 8 out of 10 to HRMY. HRMY was compared to 196 industry peers in the Pharmaceuticals industry. HRMY gets an excellent profitability rating and is at the same time showing great financial health properties. HRMY is growing strongly while it also seems undervalued. This is an interesting combination These ratings would make HRMY suitable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
HRMY had positive earnings in the past year.
HRMY had a positive operating cash flow in the past year.
HRMY had positive earnings in 4 of the past 5 years.
Of the past 5 years HRMY 4 years had a positive operating cash flow.
1.2 Ratios
HRMY has a Return On Assets of 16.33%. This is amongst the best in the industry. HRMY outperforms 95.41% of its industry peers.
HRMY's Return On Equity of 23.40% is amongst the best of the industry. HRMY outperforms 93.88% of its industry peers.
With an excellent Return On Invested Capital value of 17.95%, HRMY belongs to the best of the industry, outperforming 95.92% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for HRMY is above the industry average of 15.28%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.33% | ||
| ROE | 23.4% | ||
| ROIC | 17.95% |
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
1.3 Margins
HRMY has a better Profit Margin (23.42%) than 93.88% of its industry peers.
HRMY's Profit Margin has improved in the last couple of years.
HRMY's Operating Margin of 28.72% is amongst the best of the industry. HRMY outperforms 93.88% of its industry peers.
HRMY's Operating Margin has declined in the last couple of years.
HRMY has a Gross Margin of 78.34%. This is amongst the best in the industry. HRMY outperforms 85.71% of its industry peers.
In the last couple of years the Gross Margin of HRMY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.72% | ||
| PM (TTM) | 23.42% | ||
| GM | 78.34% |
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
2. Health
2.1 Basic Checks
HRMY has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
HRMY has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, HRMY has less shares outstanding
HRMY has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.36 indicates that HRMY is not in any danger for bankruptcy at the moment.
The Altman-Z score of HRMY (5.36) is better than 79.59% of its industry peers.
The Debt to FCF ratio of HRMY is 0.67, which is an excellent value as it means it would take HRMY, only 0.67 years of fcf income to pay off all of its debts.
HRMY has a better Debt to FCF ratio (0.67) than 95.92% of its industry peers.
A Debt/Equity ratio of 0.20 indicates that HRMY is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.20, HRMY perfoms like the industry average, outperforming 46.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | 0.67 | ||
| Altman-Z | 5.36 |
ROIC/WACC1.8
WACC9.95%
2.3 Liquidity
A Current Ratio of 3.84 indicates that HRMY has no problem at all paying its short term obligations.
HRMY has a better Current ratio (3.84) than 62.76% of its industry peers.
HRMY has a Quick Ratio of 3.80. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.80, HRMY is in the better half of the industry, outperforming 64.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.84 | ||
| Quick Ratio | 3.8 |
3. Growth
3.1 Past
HRMY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 49.76%, which is quite impressive.
HRMY shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 44.61% yearly.
The Revenue has grown by 17.74% in the past year. This is quite good.
HRMY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 160.13% yearly.
EPS 1Y (TTM)49.76%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%240%
Revenue 1Y (TTM)17.74%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%16.01%
3.2 Future
The Earnings Per Share is expected to grow by 39.17% on average over the next years. This is a very strong growth
Based on estimates for the next years, HRMY will show a quite strong growth in Revenue. The Revenue will grow by 16.93% on average per year.
EPS Next Y27.74%
EPS Next 2Y26.66%
EPS Next 3Y27.32%
EPS Next 5Y39.17%
Revenue Next Year17.83%
Revenue Next 2Y17.34%
Revenue Next 3Y16.34%
Revenue Next 5Y16.93%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 10.48, which indicates a very decent valuation of HRMY.
Based on the Price/Earnings ratio, HRMY is valued cheaper than 90.31% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.30, HRMY is valued rather cheaply.
A Price/Forward Earnings ratio of 8.07 indicates a reasonable valuation of HRMY.
HRMY's Price/Forward Earnings ratio is rather cheap when compared to the industry. HRMY is cheaper than 90.31% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.73, HRMY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.48 | ||
| Fwd PE | 8.07 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HRMY is valued cheaply inside the industry as 96.43% of the companies are valued more expensively.
93.37% of the companies in the same industry are more expensive than HRMY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.23 | ||
| EV/EBITDA | 5.9 |
4.3 Compensation for Growth
HRMY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HRMY has an outstanding profitability rating, which may justify a higher PE ratio.
HRMY's earnings are expected to grow with 27.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.38
PEG (5Y)N/A
EPS Next 2Y26.66%
EPS Next 3Y27.32%
5. Dividend
5.1 Amount
No dividends for HRMY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
32.5
+0.11 (+0.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners80.56%
Inst Owner Change1.33%
Ins Owners0.56%
Ins Owner Change-61.88%
Market Cap1.87B
Analysts78.82
Price Target51.65 (58.92%)
Short Float %9.69%
Short Ratio7.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.92%
Min EPS beat(2)-11.17%
Max EPS beat(2)31%
EPS beat(4)3
Avg EPS beat(4)12.28%
Min EPS beat(4)-11.17%
Max EPS beat(4)31%
EPS beat(8)6
Avg EPS beat(8)59.09%
EPS beat(12)9
Avg EPS beat(12)123.49%
EPS beat(16)11
Avg EPS beat(16)86.61%
Revenue beat(2)0
Avg Revenue beat(2)-2.22%
Min Revenue beat(2)-3.46%
Max Revenue beat(2)-0.98%
Revenue beat(4)0
Avg Revenue beat(4)-1.79%
Min Revenue beat(4)-3.46%
Max Revenue beat(4)-0.91%
Revenue beat(8)1
Avg Revenue beat(8)-0.9%
Revenue beat(12)3
Avg Revenue beat(12)-1.17%
Revenue beat(16)4
Avg Revenue beat(16)-1.05%
PT rev (1m)0.72%
PT rev (3m)-0.71%
EPS NQ rev (1m)-0.71%
EPS NQ rev (3m)-6.95%
EPS NY rev (1m)-4.82%
EPS NY rev (3m)-2.25%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)1.15%
Revenue NY rev (1m)-0.3%
Revenue NY rev (3m)-0.07%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.48 | ||
| Fwd PE | 8.07 | ||
| P/S | 2.42 | ||
| P/FCF | 7.23 | ||
| P/OCF | 7.22 | ||
| P/B | 2.42 | ||
| P/tB | 2.78 | ||
| EV/EBITDA | 5.9 |
EPS(TTM)3.1
EY9.54%
EPS(NY)4.03
Fwd EY12.39%
FCF(TTM)4.49
FCFY13.83%
OCF(TTM)4.5
OCFY13.86%
SpS13.43
BVpS13.44
TBVpS11.68
PEG (NY)0.38
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.33% | ||
| ROE | 23.4% | ||
| ROCE | 23.91% | ||
| ROIC | 17.95% | ||
| ROICexc | 45.94% | ||
| ROICexgc | 63.76% | ||
| OM | 28.72% | ||
| PM (TTM) | 23.42% | ||
| GM | 78.34% | ||
| FCFM | 33.46% |
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
ROICexc(3y)40.78%
ROICexc(5y)37.48%
ROICexgc(3y)77.32%
ROICexgc(5y)N/A
ROCE(3y)24.34%
ROCE(5y)20.37%
ROICexcg growth 3Y-76.77%
ROICexcg growth 5YN/A
ROICexc growth 3Y-3.89%
ROICexc growth 5YN/A
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
F-Score6
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | 0.67 | ||
| Debt/EBITDA | 0.62 | ||
| Cap/Depr | 2.7% | ||
| Cap/Sales | 0.08% | ||
| Interest Coverage | 13.83 | ||
| Cash Conversion | 105.45% | ||
| Profit Quality | 142.89% | ||
| Current Ratio | 3.84 | ||
| Quick Ratio | 3.8 | ||
| Altman-Z | 5.36 |
F-Score6
WACC9.95%
ROIC/WACC1.8
Cap/Depr(3y)59.29%
Cap/Depr(5y)142.27%
Cap/Sales(3y)3.13%
Cap/Sales(5y)8.45%
Profit Quality(3y)125.93%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.76%
EPS 3Y44.61%
EPS 5YN/A
EPS Q2Q%240%
EPS Next Y27.74%
EPS Next 2Y26.66%
EPS Next 3Y27.32%
EPS Next 5Y39.17%
Revenue 1Y (TTM)17.74%
Revenue growth 3Y32.77%
Revenue growth 5Y160.13%
Sales Q2Q%16.01%
Revenue Next Year17.83%
Revenue Next 2Y17.34%
Revenue Next 3Y16.34%
Revenue Next 5Y16.93%
EBIT growth 1Y13.95%
EBIT growth 3Y29.68%
EBIT growth 5YN/A
EBIT Next Year48.18%
EBIT Next 3Y29.62%
EBIT Next 5Y26.74%
FCF growth 1Y60.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.46%
OCF growth 3Y30.64%
OCF growth 5YN/A